Latest Commercialisation News

Strata Investment Holdings plc reported a striking £6.16 million comprehensive profit for 2025, propelled by robust investment portfolio returns and a significant revaluation uplift in its copper royalty assets. Despite operational delays from adverse weather, the company’s strategic focus on high-conviction resource investments and royalties positions it well amid evolving commodity markets.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Weebit Nano Limited has reported a remarkable 8-fold increase in revenue, driven by a landmark licensing agreement with Texas Instruments and significant progress in its ReRAM technology commercialisation.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

Dataworks Group Limited reported a significant reduction in its half-year loss alongside a major contract extension in Ontario, marking a pivotal shift to positive cash flow.

GreenHy2 Limited narrowed its net loss by 16% in FY2025, driven by government grants and initial sales of its new sodium-ion batteries. Strategic partnerships and product diversification position the company for growth in renewable energy storage.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.